128 related articles for article (PubMed ID: 9168303)
21. BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV
Mol Ther; 2001 May; 3(5 Pt 1):642-52. PubMed ID: 11356068
[TBL] [Abstract][Full Text] [Related]
22. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
23. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
24. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1).
Rosen D; Li JH; Keidar S; Markon I; Orda R; Berke G
J Immunol; 2000 Mar; 164(6):3229-35. PubMed ID: 10706715
[TBL] [Abstract][Full Text] [Related]
25. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
26. Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates apoptotic death.
Tsushima H; Imaizumi Y; Imanishi D; Fuchigami K; Tomonaga M
Exp Hematol; 1999 Mar; 27(3):433-40. PubMed ID: 10089905
[TBL] [Abstract][Full Text] [Related]
27. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines.
Fellenberg J; Mau H; Scheuerpflug C; Ewerbeck V; Debatin KM
Int J Cancer; 1997 Jul; 72(3):536-42. PubMed ID: 9247301
[TBL] [Abstract][Full Text] [Related]
28. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
29. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.
Re D; Hofmann A; Wolf J; Diehl V; Staratschek-Jox A
Exp Hematol; 2000 Jan; 28(1):31-5. PubMed ID: 10658674
[TBL] [Abstract][Full Text] [Related]
30. p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways.
Thiery J; Abouzahr S; Dorothee G; Jalil A; Richon C; Vergnon I; Mami-Chouaib F; Chouaib S
J Immunol; 2005 Jan; 174(2):871-8. PubMed ID: 15634909
[TBL] [Abstract][Full Text] [Related]
31. Induction of cell death via Fas (CD95, Apo-1) may be associated with but is not dependent on Fas-induced tyrosine phosphorylation.
Janssen O; Lengl-Janssen B; Oberg HH; Robertson MJ; Kabelitz D
Immunol Lett; 1996 Jan; 49(1-2):63-9. PubMed ID: 8964611
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis.
Posovszky C; Friesen C; Herr I; Debatin KM
Leukemia; 1999 Mar; 13(3):400-9. PubMed ID: 10086731
[TBL] [Abstract][Full Text] [Related]
33. Suppression of ERK signaling evokes autocrine Fas-mediated death in arachidonic acid-treated human chronic myeloid leukemia K562 cells.
Chen KC; Liu WH; Chang LS
J Cell Physiol; 2010 Mar; 222(3):625-34. PubMed ID: 19927299
[TBL] [Abstract][Full Text] [Related]
34. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line.
Shain KH; Landowski TH; Buyuksal I; Cantor AB; Dalton WS
Leukemia; 2000 May; 14(5):830-40. PubMed ID: 10803514
[TBL] [Abstract][Full Text] [Related]
35. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of CD95/Fas-induced DNA degradation by osmotic cell shrinkage.
Uhlemann AC; Müller C; Madlung J; Gulbins E; Lang F
Cell Physiol Biochem; 2000; 10(4):219-28. PubMed ID: 11093032
[TBL] [Abstract][Full Text] [Related]
37. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma.
Dworacki G; Meidenbauer N; Kuss I; Hoffmann TK; Gooding W; Lotze M; Whiteside TL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):947s-957s. PubMed ID: 11300496
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo.
Aragane Y; Maeda A; Cui CY; Tezuka T; Kaneda Y; Schwarz T
J Invest Dermatol; 2000 Dec; 115(6):1008-14. PubMed ID: 11121134
[TBL] [Abstract][Full Text] [Related]
39. Effects of interferon-gamma and tumour necrosis factor-alpha on CD95/Fas ligand-mediated apoptosis in human blood eosinophils.
Luttmann W; Dauer E; Schmidt S; Marx O; Hossfeld M; Matthys H; Virchow JC
Scand J Immunol; 2000 Jan; 51(1):54-9. PubMed ID: 10632976
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
